Schering-Plough Pulls Garenoxacin Application In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.
You may also be interested in...
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.